Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2010
09/10/2010CA2753664A1 Abuse resistant formulation
09/10/2010CA2753638A1 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
09/10/2010CA2753637A1 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
09/10/2010CA2753630A1 Derivatives of benzothiazines, preparation thereof and application thereof as drugs
09/10/2010CA2753552A1 N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
09/10/2010CA2753341A1 Inhibitors of bruton's tyrosine kinase
09/10/2010CA2753241A1 Process for the preparation of lenalidomide
09/10/2010CA2753236A1 Pyrrolopyrimidines used as kinase inhibitors
09/10/2010CA2753149A1 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
09/10/2010CA2753057A1 Sustained release oral dosage forms of an r-baclofen prodrug
09/10/2010CA2752804A1 Oxazole pyridine derivatives useful as s1p1 receptor agonists
09/10/2010CA2752443A1 Heterocyclic antiviral compounds
09/10/2010CA2751534A1 Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
09/10/2010CA2750862A1 Fungicidal pyrazoles
09/10/2010CA2750010A1 Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
09/10/2010CA2749352A1 Storage stable prostaglandin product
09/09/2010US20100229251 Methods and Compositions for Detecting and Treating End-Stage Cardiomyopathy Using Claudin-5
09/09/2010US20100228018 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/09/2010US20100227936 Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase
09/09/2010US20100227935 Class of terpene-derived compounds having an antibiotic activity, compositions containing the same and uses thereof
09/09/2010US20100227934 Therapeutic compounds and methods of use
09/09/2010US20100227933 Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitors
09/09/2010US20100227932 Patch
09/09/2010US20100227929 Transdermal compositions
09/09/2010US20100227928 Non-steroidal anti-inflammatory ophthalmic compositions
09/09/2010US20100227927 Salts of tramadol and naproxen and their crystal forms in the treatment of pain
09/09/2010US20100227926 Disinfectant Delivery System, and Method of Providing Alcohol-Free Disinfection
09/09/2010US20100227925 Sensitizing compound and method for increasing sexual sensitivity
09/09/2010US20100227924 Method For Producing Polyunsaturated Fatty Acids
09/09/2010US20100227923 Preventive/remedy for urinary calculosis
09/09/2010US20100227922 storage stable drug as mouth spray containing glycerol trinitrate, a triglyceride, an alcohol( ethanol, propylene glycol), a buffer ( sodium lactate, sodium phosphate and sodium stearate), water, a medium-chain partial glyceride, and a flavoring agent; treatment of angina pectoris using pump spray
09/09/2010US20100227921 Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
09/09/2010US20100227920 Aldehyde dehydrogenase inhibitors as novel depigmenting agents
09/09/2010US20100227919 Dioxaspiroketal Derivatives, Process for Their Preparation and Uses Thereof
09/09/2010US20100227918 Streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria
09/09/2010US20100227917 EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
09/09/2010US20100227916 N-desmethyl-doxepin and methods of using the same to treat sleep disorders
09/09/2010US20100227915 Compositions and methods for inhibiting expression of a gene from the jc virus
09/09/2010US20100227914 RNA Antagonist Compounds for the Inhibition of Apo-B100 Expression
09/09/2010US20100227912 RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/09/2010US20100227911 RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/09/2010US20100227910 Gene fusion targeted therapy
09/09/2010US20100227909 Compositions comprising mir34 therapeutic agents for treating cancer
09/09/2010US20100227908 Diagnostic, prognostic and treatment methods
09/09/2010US20100227907 Method of Treating Pain by Using Opioids and CAMKIV Inhibitors
09/09/2010US20100227906 C-substituted Diindolylmethane Compositions and Methods for the Treatment of Multiple Cancers
09/09/2010US20100227905 Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
09/09/2010US20100227904 Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
09/09/2010US20100227903 Polymer Formulations of CETP Inhibitors
09/09/2010US20100227902 Bis-aryl sulfonamides
09/09/2010US20100227901 Compounds for the treatment of metabolic disorders
09/09/2010US20100227899 Process for the treatment of bacterial infections using 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide
09/09/2010US20100227896 Use of vitamin pp compounds
09/09/2010US20100227895 Method for treating equine laminitis
09/09/2010US20100227894 Benzamide factor viia inhibitors useful as anticoagulants
09/09/2010US20100227892 Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases
09/09/2010US20100227891 Threshold blood omeprazole concentration is 50 ng/ml for the maintenance of intragastric ph of at least 4.0 after oral dosing with cma-omeprazole, agn 201904-z
09/09/2010US20100227890 Polymorphs of esomeprazole salts
09/09/2010US20100227889 Benzimidazole Derivatives
09/09/2010US20100227888 Modulators of cftr
09/09/2010US20100227887 Pyridine-2-yl carboxylic acid amides
09/09/2010US20100227886 Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases
09/09/2010US20100227885 Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases
09/09/2010US20100227883 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
09/09/2010US20100227882 Clopidogrel salt and polymorphic forms thereof
09/09/2010US20100227881 1,7-naphthyridine derivatives as p38 map kinase inhibitors
09/09/2010US20100227880 Chemical compounds
09/09/2010US20100227879 Liquid formulations for treatment of diseases or conditions
09/09/2010US20100227878 Noscapine analogs and their use in treating cancers, including drug-resistant cancers
09/09/2010US20100227877 New camptothecin derivatives and uses thereof
09/09/2010US20100227876 Methods of Reducing Side Effects of Analgesics
09/09/2010US20100227875 Methods for detection of biological substances
09/09/2010US20100227874 Reduction of oxidative stress damage during or after exercise
09/09/2010US20100227873 Nitrogen-containing heterocyclic compounds and methods of use thereof
09/09/2010US20100227872 Pyrazine derivatives
09/09/2010US20100227871 Nicotinic receptor agonists for the treatment of inflammatory diseases
09/09/2010US20100227870 Novel Compounds
09/09/2010US20100227869 Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands
09/09/2010US20100227868 Treatment methods with brimonidine
09/09/2010US20100227867 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
09/09/2010US20100227866 Tetrahydroisoquinolin-1-one derivative or salt thereof
09/09/2010US20100227865 Oligomer-Beta Blocker Conjugates
09/09/2010US20100227864 5-membered heterocyclic derivative and use thereof for medical purposes
09/09/2010US20100227863 Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds
09/09/2010US20100227861 IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
09/09/2010US20100227860 Disalt inhibitors of il-12 production
09/09/2010US20100227859 Tricyclic compounds as matrix metalloproteinase inhibitors
09/09/2010US20100227858 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
09/09/2010US20100227857 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
09/09/2010US20100227856 Novel compounds
09/09/2010US20100227855 Helix 12 directed non-steroidal antiandrogens
09/09/2010US20100227854 Oral Pharmaceutical Formulations Containing Non-Steroidal Anti-Inflammatory Drugs and Acid Inhibitors
09/09/2010US20100227853 Inhibitors of cyclic amp phosphodiesterases
09/09/2010US20100227852 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
09/09/2010US20100227851 Method of preventing and/or treating a neurodegenerative disease by administering an extract of Lycoris chejuensis and/or a compound isolated therefrom
09/09/2010US20100227850 Methods for preventing and treating microbial infections by modulating transcription factors
09/09/2010US20100227849 Leukemia treatment method and composition
09/09/2010US20100227848 Oxo bridged diazepan orexin receptor antagonists
09/09/2010US20100227847 Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators
09/09/2010US20100227846 Substituted pyrazole derivative
1 ... 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 ... 7860